Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Consensus Recommendation of "Moderate Buy" by Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on Artiva Biotherapeutics, with four buy ratings, one strong-buy rating, and one sell rating. The average 12-month price target is $39, compared with the recent share price of $8.51.
• ARTV reported quarterly EPS of -$0.63, in line with estimates, while analysts expect a full-year loss of approximately $2.62 per share. The stock has traded between $2.37 and $14.53 over the past year.
• Institutional investors made several significant purchases, including new stakes by 5AM Venture Management, Blue Owl Capital, and BlackRock. Separately, insiders bought substantially more shares than they sold during the latest quarter.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $39.00.

Several research firms recently commented on ARTV. Cantor Fitzgerald restated an "overweight" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, May 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Artiva Biotherapeutics in a report on Tuesday, July 21st. Needham & Company LLC restated a "buy" rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a report on Monday, June 8th. Finally, Wall Street Zen raised shares of Artiva Biotherapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 8th.

Artiva Biotherapeutics Stock Performance

Shares of ARTV stock traded up $0.07 during trading on Friday, hitting $8.51. 25,345 shares of the company were exchanged, compared to its average volume of 374,650. The business's 50-day simple moving average is $10.64 and its 200 day simple moving average is $9.10. Artiva Biotherapeutics has a twelve month low of $2.37 and a twelve month high of $14.53. The firm has a market capitalization of $415.86 million, a price-to-earnings ratio of -2.59 and a beta of 2.18.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.63) EPS for the quarter, meeting the consensus estimate of ($0.63). On average, equities analysts forecast that Artiva Biotherapeutics will post -2.62 earnings per share for the current fiscal year.

Insider Activity at Artiva Biotherapeutics

In other news, Director Ra Capital Management, L.P. purchased 120,582 shares of the company's stock in a transaction dated Tuesday, July 21st. The shares were purchased at an average price of $9.55 per share, for a total transaction of $1,151,558.10. Following the transaction, the director owned 17,098,479 shares of the company's stock, valued at approximately $163,290,474.45. This trade represents a 0.71% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Subhashis Banerjee sold 8,222 shares of the firm's stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $12.01, for a total transaction of $98,746.22. Following the sale, the insider directly owned 142,047 shares of the company's stock, valued at approximately $1,705,984.47. This trade represents a 5.47% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders purchased 406,203 shares of company stock valued at $3,937,983 and sold 32,080 shares valued at $359,739. 1.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. 5AM Venture Management LLC purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter valued at $22,827,049. Blue Owl Capital Holdings LP bought a new stake in Artiva Biotherapeutics during the second quarter worth about $8,483,000. BlackRock Inc. purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth about $6,739,000. Nantahala Capital Management LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at about $2,910,000. Finally, Alyeska Investment Group L.P. increased its position in shares of Artiva Biotherapeutics by 173.6% during the 2nd quarter. Alyeska Investment Group L.P. now owns 273,615 shares of the company's stock valued at $2,654,000 after purchasing an additional 173,615 shares during the last quarter.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing allogeneic natural killer (NK) cell therapies for cancer and autoimmune diseases. The company's platform is designed to produce off-the-shelf NK cell treatments that can be manufactured at scale and administered without requiring cells to be collected from each individual patient.

Artiva's lead product candidate, AlloNK, also known as AB-101, is an investigational allogeneic NK cell therapy intended to target and eliminate antibody-coated cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.